Skip to content

Professor Marianne ThoresenM.D., Ph.D.(Oslo)

Professor of Neonatal Neuroscience

Marianne Thoresen

Professor Marianne ThoresenM.D., Ph.D.(Oslo)

Professor of Neonatal Neuroscience

Member of

Research interests

Worldwide, newborn infants suffer death or permanent brain damage caused by diseases arising before or around the time of birth. I do translational research aimed at developing effective treatment. By integrating my studies of normal physiological changes in many organ systems with pathological changed seen during disease, I have -together with my students - developed experimental models that mimic global hypoxic-ischemic injury and brain haemorrhage leading to permanent disability in children. The neuroprotective effect of cooling newborns first presented in these models led to international clinical trials where we documented the same neuroprotective effect in humans that were cooled and this treatment is now implemented worldwide as the first effective treatment after perinatal asphyxia. With our experimental models we have shown that adding the inert gas xenon to cooling we double the neuroprotection. Xenon was, for the first time in the world, given to a baby who was cooled when our feasibilitystudy "CoolXenon" started in March 2010.

For my CV and a full list of publications, please visit my website here.

1. Circulation Physiology

Studies include

  • cerebral circulation and the influence of blood pressure, temperature and body positioning
  • cerebral venous drainage
  • positive pressure ventilation
  • cardiovascular responses to tilting
  • uterine and mammary circulation during normal pregnancy
  • skin circulation and thermoregulation
  • Physiological Method studies of Doppler velocity, electromagnetic Flowmetry, pletysmography, cerebral circulation, blood pressure and temperature.
  • Models of human disease in; newborn asphyxia, intraventricular haemorrhage

2. Neuroprotection

I have developed 3 experimental models mimicking diseases leading to permanent handicap. We use these to understand disease mechanisms and repair processes, and develop treatments for injury caused by asphyxia or low brain blood flow.

Our clinical trials have confirmed effectiveness seen in the experimental models. Now, worldwide, we are applying hypothermia after perinatal asphyxia.

Adding Xenon inhalation to hypothermia doubles neuroprotection in both small and large newborn brain injury models. Our approved Xe delivery system, with safety data and long term survival results, precedes our clinical feasibility study which is now recruiting.

View research connections